Biolidics (SGX:8YY) loss for the third quarter of the year stood at SG$420,000, down nearly 30% year over year from SG$596,000, a filing with the Singapore Exchange said on Friday.
Loss per share came in at SG$0.0006 from SG$0.0007 in the year-ago period.
The diagnostic solutions provider's revenue was up 7% year over year to SG$15,000 from SG$14,000, mainly due to a slight increase in revenue from sales of CTChip FR1 biochip.